Your session is about to expire
← Back to Search
VH3810109 + Cabotegravir for HIV (EMBRACE Trial)
EMBRACE Trial Summary
This trial evaluates if a new HIV drug combo is effective in adults already on therapy.
EMBRACE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EMBRACE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an untreated syphilis infection.I have previously received an HIV monoclonal antibody treatment.I have a history of cirrhosis, with or without hepatitis.I have been treated with cabotegravir before.I have hepatitis C.I am on a stable HIV medication regimen.My weight is between 50kg and 115kg.I am able to understand and sign the consent form.My condition is at CDC Stage 3.I am not able to have children or I am using birth control.I am currently experiencing or have a history of significant pancreatitis.I have not received an HIV-1 vaccine in the last 90 days.I have an ongoing chronic hepatitis B infection.I don't have conditions affecting how my body handles medication.I have been on my first or second HIV medication without changes for at least 6 months.I have a specific skin condition.
Frequently Asked Questions
Who is eligible to enroll in the clinical trial?
"This clinical trial seeks roughly 150 participants aged between 18 and 70, who have been diagnosed with human immunodeficiency virus infection."
Is this research endeavor actively seeking participants?
"According to clinicaltrials.gov, recruitment for this medical study has concluded as the most recent changes were made on August 9th 2023. Nevertheless, there are still 456 other trials looking for patients at present."
Does this investigation accommodate individuals aged thirty or older?
"This trial is open to patients aged between 18 and 70. Those under the age of 18 have access to 111 other studies, while those over 65 can select from 337 different trials."
How many venues is the clinical trial being conducted in?
"Presently, this trial is deploying personnel to 39 medical centres for patient recruitment. Locations include Bakersfield, Los Angeles and Palm Springs as well as 36 other destinations. To reduce the burden of travelling far distances, it may be wise to pick a nearby centre if you choose to partake in the study."
What is the Food and Drug Administration's stance on administering VH3810109 in combination with cabotegravir?
"Our team at Power gave VH3810109 Plus Cabotegravir a rating of 2 due to there being preliminary clinical evidence in its favour for safety, but none yet regarding efficacy."
Share this study with friends
Copy Link
Messenger